|
Adenocarcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
A 69-year-old Caucasian female former light-smoker presented with stage IV EGFR L858R positive adenocarcinoma who developed EGFR T790M mutation after 8 month treatment of erlotinib.
|
28625641 |
2017 |
|
Adenocarcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
A gefitinib-resistant point mutation (T790M) in exon 20 without gefitinib treatment was detected in 1 AAH and 1 adenocarcinoma.
|
17561305 |
2007 |
|
Adenocarcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
A lung biopsy from the left lower lobe disclosed an adenocarcinoma which harbored an in-frame deletion in exon 19 (heterozygous delE746-A750) of EGFR without a second mutation such as T790M in exon 20.
|
17618013 |
2007 |
|
Adenocarcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Acquired resistance of pulmonary adenocarcinoma to initially successful targeted therapy due to EGFR mutation T790M.
|
17649787 |
2007 |
|
Adenocarcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
After 12 mo of treatment with icotinib, ovarian biopsy showed adenocarcinoma with CDX2(-), TTF-1(+++), PAX8(-), CK-7(+++), CK-20(++), and Ki67(15%+), accompanied with EGFR 19-del mutation and T790M mutation.
|
31363481 |
2019 |
|
Adenocarcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Both sporadic and germline T790M mutations were predominantly adenocarcinomas, favored female gender, and were occasionally multifocal.
|
24736066 |
2014 |
|
Adenocarcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Cytological examination of the pleural effusion confirmed an adenocarcinoma positive for the <i>EGFR</i> exon 19 deletion and the T790M mutation within exon 20, while a biopsy from the upper left bronchus revealed a keratinizing squamous cell carcinoma positive for the <i>EGFR</i> exon 19 deletion.
|
29113230 |
2017 |
|
Adenocarcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Exon 20 T790M point mutation (T790M) was detected in 3 squamous carcinomas and 3 adenocarcinomas and exon 20 insertion mutation (20-ins) was detected in 2 patients with adenocarcinoma.
|
24351833 |
2013 |
|
Adenocarcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
However, after completing 6 cycles of this combination, new pulmonary and hepatic metastases appeared and showed persistence of the original EGFR- and FGFR3-mutated ADC phenotype together with acquisition of the erlotinib-resistant T790M EGFR-mutation.
|
29110841 |
2017 |
|
Adenocarcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Most of T790M mutations were frequently associated with non-smoker, adenocarcinoma and EGFR activating mutations.
|
19381876 |
2009 |
|
Adenocarcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Osimertinib is commonly used in pulmonary adenocarcinoma patients who are resistant to first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors and carry the T790M mutation.
|
30233215 |
2018 |
|
Adenocarcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Small cell carcinoma transformation was identified in four patients; none had p.T790M, including two where p.T790M was identified in the co-existing adenocarcinoma.
|
27304188 |
2016 |
|
Adenocarcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Squamous Cell Carcinoma "Transformation" Concurrent with Secondary T790M Mutation in Resistant EGFR-Mutated Adenocarcinomas.
|
26746366 |
2016 |
|
Adenocarcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Three metastatic/recurrent adenocarcinomas demonstrated an additional EGFR T790M mutation that was not identified in the original specimens.
|
23495083 |
2013 |
|
Adenocarcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Using histological and gene sequencing analysis, we observed that the primary adenocarcinoma acquired T790M mutation in EGFR exon 20, and a secondary sarcomatoid carcinoma developed in the vicinity.
|
28786540 |
2017 |
|
Adenocarcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
We also identified the TKI drug resistance-associated EGFR T790M mutation in an untreated case of Barrett's esophagus and the corresponding adenocarcinoma.
|
16857803 |
2006 |
|
Adenocarcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
We analyzed 147 NSCLC tissues [70 adenocarcinomas (AD), 62 squamous cell carcinomas (SQ), 12 large cell carcinomas (LC), and three adenosquamous carcinomas] that had not been exposed to the TKI therapies, and found 12 (8.2%; 12/147) EGFR T790M mutation in eight AD (11.4%), three SQ (4.8%), and one LC (8.3%) by the PNA-clamping PCR.
|
21635547 |
2011 |
|
Adenocarcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
We analyzed three major EGFR mutations (L858R in exon 21, E746_A750del in exon 19 and T790M in exon 20) in 80 fresh liquid cytology specimens of adenocarcinoma (ADC) or NSCLC-not otherwise specified (NOS) via the EGFR d-PCR assay and conventional real-time PCR assay using the therascreen® EGFR RGQ PCR kit (Therascreen assay).
|
27922678 |
2017 |
|
Adenocarcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
We report 3 cases of pulmonary adenocarcinoma which did not respond to EGFR-TKI retreatment even with T790M disappearance.
|
30145590 |
2018 |
|
Adenocarcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
We studied the prevalence of T790M mutation among pulmonary adenocarcinoma patients in Lebanese patients based on liquid biopsy testing the circulating tumor DNA (ctDNA).
|
31147859 |
2019 |